Regulatory moats in health technology
FDA clearances, clinical datasets, and regulatory approvals create durable barriers. Where a competitor needs years and capital to replicate a position, we see defensible value.
Choi & Park Investment
Early and growth-stage capital for deep technology in regulated, high-barrier markets.
We invest in companies building defensible technology in regulated, high-barrier markets — where clearances, data, and infrastructure create moats that capital alone cannot replicate. We back founders across the United States, from clinical health technology to the infrastructure beneath AI.
Who we are
Choi & Park Investment is a private investment firm founded by Minkyu Choi and Joshua Park. We deploy our own capital into private companies at the growth and pre-IPO stages, through direct participation and special purpose vehicles alongside institutional leads.
- Firm
- Private investment firm
- Managing Partners
- Minkyu Choi · Joshua Park
- Stage
- Growth & pre-IPO
- Structure
- Direct & SPV, alongside institutional leads
- Focus
- United States
- Portfolio
- Xandar Kardian
Investment thesis
Three pillars
We concentrate where barriers are structural rather than temporary — and where a head start compounds instead of eroding.
AI infrastructure and physical scarcity
Power, land, and grid interconnection are the binding constraints of this cycle — not chips or models. We back contracted capacity and the infrastructure beneath the compute layer.
Secure enterprise deployment
Healthcare, financial services, and government adopt slowly and switch rarely. We look for companies positioned at that edge, where an early win compounds into a durable moat.
Portfolio
Xandar Kardian
Contactless health monitoring
- Sector
- Health technology
- Location
- Toronto & Seoul
- Stage
- Series B
- Regulatory
- FDA 510(k) cleared
- Holding
- Active
Impulse UWB radar that measures heart rate, respiration, and movement continuously — without wearables or cameras. FDA-cleared since 2021, with deployments across 210+ correctional facilities, skilled nursing, behavioral health, and hospital pilots including Mayo Clinic.
Why we invested
A regulatory head start that compounds, a clinical outcome dataset that cannot be bought or scraped, and inbound licensing interest from four Tier-1 electronics manufacturers who tried to build the same capability internally and could not.
Forward view
The next decade of returns in private technology will be determined less by category selection than by entry discipline. Capital is abundant; price discipline is not.